GeneChem
North America, Quebec, Canada, Montréal
Description
GeneChem fund and the changing landscape of the genomics industry, the principals set out to raise their second focused fund, GeneChem
Investor Profile
GeneChem has made 28 investments, with 0 in the past 12 months and 4% as lead.
Stage Focus
- Series Unknown (29%)
- Series B (25%)
- Series A (18%)
- Series C (11%)
- Convertible Note (4%)
- Post Ipo Equity (4%)
- Series D (4%)
- Series E (4%)
- Private Equity (4%)
Country Focus
- United States (79%)
- Canada (18%)
- United Kingdom (4%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
Industry Focus
- Biotechnology
- Medical
- Pharmaceutical
- Health Care
- Clinical Trials
- Biopharma
- Therapeutics
- Information Technology
- Messaging
- Bioinformatics
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
